Dixon Hubard Feinour & Brown’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-131
Closed -$50K 214
2021
Q1
$50K Hold
131
0.01% 204
2020
Q4
$50K Hold
131
0.01% 179
2020
Q3
$50K Hold
131
0.01% 179
2020
Q2
$59K Hold
131
0.02% 183
2020
Q1
$48K Hold
131
0.02% 165
2019
Q4
$93K Hold
131
0.02% 179
2019
Q3
$84K Hold
131
0.02% 176
2019
Q2
$115K Hold
131
0.03% 177
2019
Q1
$76K Hold
131
0.02% 171
2018
Q4
$37K Hold
131
0.01% 162
2018
Q3
$63K Hold
131
0.02% 177
2018
Q2
$59K Hold
131
0.02% 165
2018
Q1
$77K Hold
131
0.02% 188
2017
Q4
$81K Sell
131
-52
-28% -$37.4K 0.02% 188
2017
Q3
$168K Hold
183
0.05% 177
2017
Q2
$170K Hold
183
0.05% 176
2017
Q1
$174K Hold
183
0.05% 175
2016
Q4
$147K Hold
183
0.05% 167
2016
Q3
$154K Sell
183
-33
-15% -$26.5K 0.05% 168
2016
Q2
$178K Hold
216
0.06% 164
2016
Q1
$255K Hold
216
0.08% 144
2015
Q4
$269K Buy
216
+1
+0.5% +$1.65K 0.09% 140
2015
Q3
$291K Buy
215
+106
+97% +$175K 0.11% 127
2015
Q2
$197K Buy
+109
New +$169K 0.06% 178

Other funds holding TCRT

Dixon Hubard Feinour & Brown's TCRT Position: Q2 2021 in Review

Dixon Hubard Feinour & Brown sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 131 shares — an estimated $50K sold.

Dixon Hubard Feinour & Brown first reported a position in TCRT in Q2 2015 and held it in 24 quarters. The position peaked at $291K in Q3 2015. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

  • Dixon Hubard Feinour & Brown reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Dixon Hubard Feinour & Brown sold 131 Alaunos Therapeutics shares in Q2 2021, an estimated $50K.
  • Dixon Hubard Feinour & Brown first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 24 quarters.
  • Dixon Hubard Feinour & Brown's Alaunos Therapeutics position peaked at $291K in Q3 2015.
  • 155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2021, filed 23 Aug 2021.